Table 4.
SARS-CoV and MERS-CoV vaccines in development.
| Name | Developer | Vaccine Type | Clinical Outcome(s) | Comments | Trial Phase |
|---|---|---|---|---|---|
| SARS-CoV | |||||
| N/A | Sinovac | Inactivated vaccine | Contributed to 100% seroconversion following 2 vaccine doses of 16 SU | Short-term systemic adverse events (all subjects) |
Phase 1 |
| N/A | NIH, NIAID (Vaccine Research Center) | Recombinant DNA vaccine | CD4+ T-cell response (All subjects) CD8+ T-cell response (20% of subjects) |
Mild systemic reactions observed (~50% of subjects) |
Phase 1 |
| MERS-CoV | |||||
| GLS 5300 | Inovio Pharmaceuticals, Inc. | DNA vaccine | Associated with seroconversion and nAb development against MERS-COV viral infection | Immune protection lasted for one year after vaccination | Phase 1 |
| ChAdOx1 MERS | Oxford University | ChAdOx1 vector | Associated with immune protection, seroconversion, and T-cell response | Immune protection lasted for a year after vaccination | Phase 1 |
Abbreviations: nAb = neutralizing antibody; NIH = National Institute of Health; NIAID = National Institute of Allergy and Infectious Disease; MVA = modified vaccinia virus Ankara; ChAdOx1 = chimpanzee adenovirus.